originally published at Health - Trend Magazine
Reports And Data
Rise in number of cancer patients has led to rise in investments from government to establish specialized hospitals, which is expected to drive revenue growth
NEW YORK, NY, UNITED STATES, April 15, 2022 /EINPresswire.com/ — The global cancer biomarker market size is expected to reach USD 50.19 Billion in 2030 and register a revenue CAGR of 11.7% over the forecast period, according to the latest report by Reports and Data. Rapid market revenue growth of cancer biomarker is due to various factors such as technological advancements and increasing use of personalized medicine. However, high capital investments and low benefit-cost ratio are certain restraints that can affect market revenue growth.
Biomarkers plays a crucial role in identifying the presence of cancer within the body. It also helps in identifying the intensity to which cancer has spread within the body. A biomarker is a biological molecule found in blood, other body fluids, or tissues and signals a normal or abnormal process, or of a condition or disease. Increasing R&D in laboratories has led to introduction of new biomarkers for identifying specific cancers. Rise in number of cancer patients across the globe has led to a demand for better diagnostic techniques. If a patient is diagnosed early and has been confirmed with cancer, then it becomes easy for doctors to treat him or her well. Biomarkers help in detecting cancer at an early stage via different profiling technologies. Rise in awareness programs for early diagnosis of cancer has also led to increase in demand of profiling technologies.
Biomarkers help in identifying the presence of tumor cells within the body with a high efficacy rate instead of going through large number of tests. During diagnosis, if biomarker is used for identifying the cancer then it can reduce the cost of testing. Low cost, easily accessibility and quick results are certain benefits of using biomarkers for diagnosing cancer, which is expected to drive market revenue growth.
Get a sample of the report @
Some Key Highlights from the Report
By biomolecule type, proteomic segment accounted for the largest revenue share in 2020. Proteomics field has seen immense development over the past few years. Technological advancements in the field have facilitated enhancement of sample multiplexing ability, identification of protein interactions and sensitivity. Proteomic biomarker technologies have the potential to analyze multiple proteins, and such technologies include mass spectrometry and protein microarray.
By application, prognostics segment accounted for largest market revenue share in 2020. Biomarkers in cancer treatment can be used for disease prognosis which takes place after an individual has been diagnosed with cancer. Biomarkers can be useful in determining the aggressiveness of an identified cancer as well as its likelihood of responding to a given treatment. Prognostic biomarker include elevated levels of metallopeptidase inhibitor 1(TIMP1), a marker associated with more aggressive forms of multiple myeloma and many more. Prognosis helps in complete removal of cancer cells within the body, and thus such an application is expected to drive the segment revenue growth.
Cancer Biomarker Market in North America accounted for largest revenue share in 2020. The region has an extremely advanced healthcare sector, which engages itself in continuous R&D activities for innovative product launches. The region serves as the headquarters for a plethora of key players operating in the market. Countries in this region have high incidence rate of cancer, consequently leading to an escalating demand for novel as well as effective therapeutic modalities.
Cancer biomarkers market in the Asia Pacific region is expected to register a faster revenue CAGR during the forecast period due to rapid healthcare infrastructural developments, increasing technological developments and expansion of the R&D activities in the region. Countries such as India and China have untapped potential, which is further expected to drive the developments in the regional market.
In January 2022, Thermo Fisher Scientific Inc. and PeproTech Inc. announced that Thermo Fisher Scientific had completed its acquisition of PeproTech. PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models.
Companies profiled in the global market report include Abbott Laboratories Ltd., Celera Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., GE Healthcare Systems, Becton, Dickson & Company, Quest Diagnostics Inc., Genomic Health, Inc., and Hologic Inc.
To know more about the report @
Cancer Biomarker Market Segmentation:
Biomolecule Type Outlook (Revenue, USD Million; 2018–2030)
Profiling Technologies Outlook (Revenue, USD Million; 2018–2030)
Cytogenetics based tests
Services Outlook (Revenue, USD Million; 2018–2030)
Biomarkers and Testing
Diseases Type Outlook (Revenue, USD Million; 2018–2030)
Application Outlook (Revenue, USD Million; 2018–2030)
Global Cancer Biomarker Market Report: Regional Segmentation
Rest of Europe
Rest of APAC
Rest of LATAM
Middle East & Africa
Rest of MEA
Download Summary @
Global Cancer Biomarker Market: Table of Contents
Chapter 1. Methodology & Sources
1.1. Market Definition
1.2. Research Scope
1.4. Research Sources
1.4.1. Primary Sources
1.4.2. Secondary Sources
1.4.3. Paid Sources
1.5. Market Estimation Technique
Chapter 2. Executive Summary
Chapter 3. Key Insights
Chapter 4. Global Pharma & Healthcare Market Segmentation
4.1. Global Pharma & Healthcare Market COVID-19 Impact Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers’ analysis
4.2.3. Market restraints analysis
4.3. Technological Insights
4.4. Porter’s Five Forces Analysis
4.5. Regulatory Framework
4.6. Price trend Analysis
4.7. Competitive Metric Space Analysis
Request a customization of the report @
Frequently Asked Questions Answered in the Report:
What is the estimated revenue growth rate of the global Cancer Biomarker market over the forecast period?
What are the major factors driving the global market revenue growth?
Which are the leading manufacturers and suppliers in the global Cancer Biomarker market?
Which regional market is expected to lead in terms of revenue share in the global Cancer Biomarker market over the forecast years?
What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis of the market?
Thank you for reading our report. Please connect with us to know more about the report and its customization feature. Our team will ensure the report is well suited to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Reports and Data
email us here
Visit us on social media:
originally published at https://thetrendmag.comHealth - Trend Magazine